What would be your approach to initial treatment of a patient with standard-risk myeloma unwilling to undergo autologous stem cell transplant, if practicing in a resource-limited setting?

For non-transplant candidates or patients unwilling to have transplant with standard risk MM, these are my 2 choices:

1. RVd: len/velcade/dex: based on the SWOG S077 compared to Rd: Durie et al., PMID 28017406.
2. Dara Rd: Daratumumab/Revlimid/dex: based on the MAIA study compared to Rd: Facon et al., PMI...